Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
Patients with mechanical heart valves (MHVs) are at a higher risk for thromboembolic events than patients with atrial fibrillation (AF). This difference is observed in the higher maintenance international normalized ratio (INR) range for patients with MHV and in the selection for anticoagulation bridge therapy when warfarin is interrupted perioperatively. However, once the decision is made to "bridge," the same therapeutic options, unfractionated heparin and subcutaneous low-molecular-weight heparin (LMWH), are applicable to the 2 patient populations. Unfractionated heparin requires extended hospitalization and is often not selected. A paucity of published data exist establishing the efficacy and safety of LMWH as a bridging agent. The aim of this study was to describe a single-center experience and to provide data supporting the use of enoxaparin as a bridging agent. The study assessed whether patients with MHV undergoing bridging for a variety of procedures had higher thromboembolic and hemorrhagic risk compared to patients with nonvalvular AF. We performed a retrospective cohort study of 173 patients (with MHV and AF) who underwent 230 bridging episodes with an LMWH, enoxaparin, from February 2002 through September 2007. Main outcome measurements were the incidence of thromboembolic and hemorrhagic events within 2 months after the procedure. Of total bridging episodes, 130 episodes met the inclusion criteria; 62 episodes occurred in the MHV population and 68 episodes occurred in the AF population. The procedures varied from minor invasive procedures to major surgeries. There were no deaths or thromboembolic events. Major and minor bleeding rates were similar between the MHV and AF groups (3.2% and 2.9%, 14.5% and 13.2% respectively, p = NS). The major bleeding rate was similar to published data on bridging therapy. Most bleeding episodes (73%) occurred within 7 days after the procedure. In conclusion, our study provided actual outpatient anticoagulation clinical data on using LMWH as an option for periprocedural bridging anticoagulation in patients with MHV.
Bui
Hien Thuy
HT
Division of Pharmacy, Kaiser Permanente San Jose Medical Center, San Jose, California, USA. mazhtb@hotmail.com
Krisnaswami
Ashok
A
Le
Chieu-Uyen
CU
Chan
James
J
Shenoy
Bach-Nga
BN
D000368:Aged; D000553:Ambulatory Care; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000453:epidemiology*; D015331:Cohort Studies; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D006350:Heart Valve Prosthesis; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011292:Premedication; D012189:Retrospective Studies; D013514:Surgical Procedures, Operative; D013923:Thromboembolism / Q000453:epidemiology / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin